Navigation Links
Micromet, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
Date:3/13/2008

from Merck Serono following the completion of two phase 2 clinical trials for adecatumumab. Total operating expenses were $13.1 million for the three months ended December 31, 2007, compared to $10.9 million for the same period in 2006. For the three months ended December 31, 2007, Micromet reported a net loss of $3.8 million, or $0.09 per basic and diluted share, compared to net income of $3.4 million, or $0.11 per basic and diluted share, for the same period in 2006. The positive net income in 2006 was due primarily to the milestone payment received from Merck Serono.

Year Ended December 31, 2007

Revenues for the year ended December 31, 2007 were $18.4 million, compared to $27.6 million for 2006. For the year ended December 31, 2007, Micromet reported operating expenses of $43.6 million, compared to $61.2 million for the same period in 2006. In connection with the merger with CancerVax, Micromet recorded a non-recurring, non-cash charge of $20.9 million in the second quarter of 2006 due to the immediate write-off of CancerVax's in- process research and development programs. For the year ended December 31, 2007, net loss was $20.1 million, or $0.55 per basic and diluted share, compared to $34.0 million, or $1.29 per basic and diluted share, for 2006.

Micromet's cash and cash equivalents were $27.1 million as of December 31, 2007. Net cash used in operating activities was $14.3 million for the year ended December 31, 2007 and $15.4 million in 2006. Based on the status of our development programs, management believes that the cash balance at December 31, 2007 is sufficient to fund operations into the second quarter of 2009.

2008 Outlook:

-- Micromet will present an update on its proprietary BiTE antibody

technology platform and new BiTE antibody programs at the conference of

the American Association of Cancer Research (AACR) in April 2008.

-- A phase 1/2 clinical trial evaluating MT103 in patients wi
'/>"/>

SOURCE Micromet, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Micromet, Inc. to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results
2. Micromet, Inc. Elects Joseph P. Slattery to Board of Directors
3. Micromet, Inc. to Present at the Sal. Oppenheim 2nd European Healthcare Conference
4. Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
5. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
6. Helix BioPharma reports Q2 2008 highlights, financial results
7. Oncothyreon reports full year and fourth quarter 2007 financial results
8. Palatin Technologies, Inc. Reports Positive Results of a Phase I Clinical Study With PL-3994 for the Treatment of Congestive Heart Failure
9. Alfacell Reports Financial Results for Second Quarter of Fiscal 2008
10. ISTA Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
11. Oncolytics Biotech Inc. Reports Highlights and Financial Results for 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 2015   GenoSpace , a precision medicine software company that ... broad use of genomic, imaging and other biomedical data in ... Michelle Munson , CEO of Aspera, an IBM Company, to ... http://photos.prnewswire.com/prnh/20150122/170713 "We are pleased to ...
(Date:12/24/2014)... NEW YORK , Dec. 24, 2014 PlasmaTech ... care in critical areas, announced the closing of an underwritten ... to purchase up to an aggregate 3,500,000 shares of common ... $.01 per warrant.  The warrants have a per share exercise ...
(Date:12/24/2014)... GMO corn cases filed across the United States, ... of being consolidated in a Kansas federal court for pretrial ... 162 Corn Litigation, MDL No. 2591 in the U.S. District ... Syngenta GMO corn multidistrict litigation (MDL) has been handed over ...
(Date:12/24/2014)... New York (PRWEB) December 23, 2014 According ... the Long Island Affiliate of ITRA Global, the national office ... but steady recovery. This is evidenced by the third ... strong stock market. Low energy costs have held inflation ...
Breaking Biology Technology:GenoSpace Expands Board with Appointment of Michelle Munson 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2ITRA Global Reports Long Island Is Out of Sync With The National Office Market 2ITRA Global Reports Long Island Is Out of Sync With The National Office Market 3
... GPRO ) announced today that the Company will ... 31, 2008 at approximately,4:00 p.m. Eastern Time (ET). The ... p.m. ET. Hank Nordhoff, chairman and chief,executive officer, and ... will host the call., The conference call will ...
... merit and part of its overall strategy to, cripple PSC, force PSC to ... for failing to provide funding to ... PSC., -- ... FDA approval for its lead vaccine product, FluBlok, ...
... , - 1st Half-Year Sales Up 16%, - Revision Upwards of 2008 Sales Growth Guidance: (greater than or equal,to)12%, EUR millions ... 2008 08/07 ... ... 20.5 72 23.2 72 13 26.8 71 15 ...
Cached Biology Technology:Gen-Probe Announces Webcast of Second Quarter 2008 Earnings Conference Call 2Protein Sciences Responds to Emergent BioSolutions Lawsuit 2Protein Sciences Responds to Emergent BioSolutions Lawsuit 3Protein Sciences Responds to Emergent BioSolutions Lawsuit 4Protein Sciences Responds to Emergent BioSolutions Lawsuit 5Stallergenes: Q2 2008 Sales up 18% Revision Upwards of 2008 Sales Growth 2
(Date:1/22/2015)... NXTD and NXTDW) a biometric authentication company focused on ... Wocket™ smart wallet at CES 2015 in Las Vegas ... the "11 Hot Products at CES" in a review published in Wired.com, ... Newseveryday.com and "The top 10 gadgets from CES 2015" by Danny ...
(Date:1/22/2015)... , Jan. 21, 2015  Analyst Report Issued by Small Cap ... report showed that planet-wide, transactions at merchants on the leading ... total number of credit, debit, and prepaid cards reached 6.54 ... victims of fraudulent card usage in 2012, and credit and ...
(Date:1/22/2015)... , Jan. 22, 2015 Research and Markets ... addition of the "Global Wearable Technologies Market ... Share, Overview, Trends and Forecast 2014-2020" report ... Technologies are smart devices that can be worn ...
Breaking Biology News(10 mins):CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 3$4.80 Near Term Price Target with "Buy" given by CapRock Research for NXT-ID, Inc. (NASDAQ: NXTD) issued by Small Cap IR 2Global Wearable Technologies Market and Applications, Opportunities, Industry Analysis, Segmentation, Size, Growth, Share, Overview, Trends and Forecast 2014-2020 2
... by a scientist at Fred Hutchinson Cancer Research Center ... common form of muscular dystrophy. The findings, published online ... the team,s series of groundbreaking discoveries begun in 2010 ... FSHD., The team, co-led by Stephen Tapscott, M.D., ...
... just catch our eyes, they catch those of pollinators like ... Because plants need to maximize the opportunity for pollinators to ... flowering can have profound effects on flower, fruit, and seed ... major driving forces of flowering are external factors such as ...
... at the U.S. Department of Energy,s (DOE) SLAC National ... of the electrons from xenon atoms, creating a "supercharged," ... The findings, which defy expectations and theory, could ... needed to study extreme states of matter or ward ...
Cached Biology News:Researchers discover 2 genetic flaws behind common form of inherited muscular dystrophy 2CSHL-led team discovers new way in which plants control flower production 2CSHL-led team discovers new way in which plants control flower production 3Study provides recipe for 'supercharging' atoms with X-ray laser 2Study provides recipe for 'supercharging' atoms with X-ray laser 3
... Agencourt AMPure is a ... that requires no sample transfer, ... efficiently purifies small and large ... or 384-well microplates. Agencourt AMPure ...
... These 1.5L PYREX trypsinizing flasks ... tissue samples into cell suspensions ... Heavy beaded neck accepts cotton ... vigorous agitation. • Height of ...
... kit for stabilizing 50g of purified RNA samples ... Kit delivers all of the advantages and applications ... addition the RNA can be used for enzymatic ... product has been optimised for the stabilization of ...
... PYREX Fernbach-style culture flasks have triple baffles ... bottom to achieve maximal oxygen transfer to ... marking spot., A wide range of optional ... Polypropylene colored caps for ease of ...
Biology Products: